Federal Circuit Holds Post-Invention Funding Agreement Subject to Government Licensing Provision of Bayh-Dole Act

March 15, 2024

Reading Time : 2 min

The Federal Circuit held that a subcontractor’s receipt of retroactive payment from a government grant brought the subcontractor’s work under Bayh-Dole even though the work was performed before the contract was entered into. In so doing, the Federal Circuit determined that the government had a license to the patent at issue because the invention was actually reduced to practice by individuals who were later paid for the work under a subcontract of an NIH grant.

The relevant inventions related to transgenic mice that develop Alzheimer’s disease at an accelerated rate. The mice were first developed by four scientists at the University of South Florida (USF), one of whom submitted an application in 1995 for NIH funding to support the work. All four scientists were identified as people who were expected to contribute to work associated with the grant. Shortly after the project began, two of the scientists moved to the Mayo Clinic. And shortly after that, in September 1996, the NIH awarded the grant to Mayo.  The mice, however, remained housed at USF. In April 1997, the two scientists remaining at USF informed the two scientists at the Mayo Clinic that they had successfully observed the development of Alzheimer’s pathology in mice, i.e., the inventions were actually reduced to practice in April 1997.

More than a year after the grant was awarded, Mayo and USF entered into a subcontract, which expressly stated that it was executed to comply with the NIH guidelines that require such contracts when grant-covered work occurs at a different institute. The effective date of the subcontract was September 1997. It was undisputed that the April 1997 work performed by USF was covered by the NIH grant, and that USF accepted grant funds from Mayo for the April 1997 work. Based on these facts, the Court of Federal Claims found Bayh-Dole applied to the USF patents because the mice were actually reduced to practice in the performance of work under a funding agreement.

On appeal, USF argued that Bayh-Dole did not apply because the subcontract was not in place at the time of the work and because there was no legally adequate implied agreement in place when the April 1997 work was performed.

The Federal Circuit rejected both arguments, holding that Bayh-Dole broadly defines “funding agreement” to include any subcontract of any type, which must be interpreted to include payment for work already performed before the subcontract is executed or its effective date. The court found this interpretation confirmed by USF’s own position that Mayo paid it retroactively with grant funds for the April 1997 work. The Federal Circuit also remarked that its conclusion was bolstered by the fact that it is not uncommon for subcontracts of this type to be executed after a federal grant is awarded, even though work under the grant begins beforehand. According to the Federal Circuit, this practice supports looking to the facts of the agreement and actual funding, as it did here.

Practice Tip: When evaluating the applicability of Bayh-Dole to intellectual property, parties should look at the factual circumstances around conception, reduction to practice and how the funding was treated by those involved, as this decision makes clear that the timing of payment of funds or execution/effect of any subcontracts is not likely to be determinative.

Univ. of S. Fla. Bd. Of Trustees v. United States, 92 F. 4th 1072 (Fed. Cir. 2024)

Share This Insight

Previous Entries

IP Newsflash

January 17, 2025

The District of Delaware recently denied a motion to dismiss a patent infringement complaint involving gene editing technology that sought relief under the Safe Harbor Provision of the Hatch-Waxman Act. Specifically, the court found the patentee’s complaint sufficiently alleged at least some uses of the claimed technology that, when taken as true, were not solely uses of a “patented invention” that were “reasonably related” to an FDA submission.

...

Read More

IP Newsflash

January 17, 2025

The District of Arizona recently held that a plaintiff’s failure to mark patented products during the time period that marking was required barred it from recovering all pre-notice damages, including for a period of time when there was no obligation to mark.

...

Read More

IP Newsflash

January 16, 2025

The Unified Patent Court (UPC) aims to provide expeditious decisions for its litigants. That means that there is a higher bar for obtaining extensions of time. As exemplified in BMW v. ITCiCo, the UPC’s reluctance to grant extensions can have serious consequences, including revocation of the patent.

...

Read More

IP Newsflash

January 15, 2025

The Patent Trial and Appeal Board granted institution of inter partes review of a patent directed to delivery of targeted television advertisements. The board rejected patent owner’s argument that a lack of particularity as to the asserted grounds justified denial under 35 U.S.C. § 312(a), holding that “simply including a significant amount of testimony and a number of supporting references is not, by itself, a reason to find that the particularity requirement is not met.”

...

Read More

IP Newsflash

December 2, 2024

The Patent Trial and Appeal Board determined that a reference could be used as prior art because patent owner failed to provide sufficient evidence that the prior art’s disclosure was invented by all four named inventors, and thus the same “inventive entity,” as the challenged claims.

...

Read More

IP Newsflash

December 2, 2024

The Patent Trial and Appeal Board rejected a patent owner’s assertion that petitioner should have named a third party, which was a defendant in a related district court patent infringement litigation and a party to a joint defense agreement (JDA) with petitioner, as a real party-in-interest (RPI). Had the board ruled otherwise and found the third party to be an RPI, the petition would have been time-barred under 35 U.S.C. § 315(b).

...

Read More

IP Newsflash

November 27, 2024

A district court recently refused to exclude testimony regarding consumer surveys conducted by a design patent expert, holding instead that the consumer surveys may be probative of how an ordinary observer would view the designs at issue, and thus could assist the factfinder in determining design patent infringement under the ordinary observer test.

...

Read More

IP Newsflash

November 5, 2024

The Federal Circuit vacated a district court’s fee award because the district court considered certain information that was not relevant to the question of whether plaintiff’s case was exceptional. Specifically, the Federal Circuit held that only those “red flags” that related to the successful Section 101 defense, which served as the basis for the district court’s grant of summary judgment, could be used to show the case was fatally flawed.   

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.